Cargando…

The impact of bevacizumab treatment on survival and quality of life in newly diagnosed glioblastoma patients

Glioblastoma multiforme (GBM) remains one of the most devastating tumors, and patients have a median survival of 15 months despite aggressive local and systemic therapy, including maximal surgical resection, radiation therapy, and concomitant and adjuvant temozolomide. The purpose of antineoplastic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poulsen, Hans Skovgaard, Urup, Thomas, Michaelsen, Signe Regner, Staberg, Mikkel, Villingshøj, Mette, Lassen, Ulrik
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2014
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186574/ https://www.ncbi.nlm.nih.gov/pubmed/25298738 http://dx.doi.org/10.2147/CMAR.S39306

Ejemplares similares

Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitro
por: Staberg, Mikkel, et al.
Publicado: (2016)

VEGF-C sustains VEGFR2 activation under bevacizumab therapy and promotes glioblastoma maintenance
por: Michaelsen, Signe R, et al.
Publicado: (2018)

Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastoma
por: Urup, Thomas, et al.
Publicado: (2020)

Targeting glioma stem‐like cell survival and chemoresistance through inhibition of lysine‐specific histone demethylase KDM2B
por: Staberg, Mikkel, et al.
Publicado: (2018)

(18)F-FET MicroPET and MicroMRI for Anti-VEGF and Anti-PlGF Response Assessment in an Orthotopic Murine Model of Human Glioblastoma
por: Nedergaard, Mette Kjoelhede, et al.
Publicado: (2015)

Transcriptional changes induced by bevacizumab combination therapy in responding and non-responding recurrent glioblastoma patients
por: Urup, Thomas, et al.
Publicado: (2017)

Extracranial metastases in glioblastoma—Two case stories
por: Schou Nørøxe, Dorte, et al.
Publicado: (2018)

Cell-free DNA in newly diagnosed patients with glioblastoma – a clinical prospective feasibility study
por: Nørøxe, Dorte Schou, et al.
Publicado: (2019)

DNA Methylation Levels of the ELMO Gene Promoter CpG Islands in Human Glioblastomas
por: Michaelsen, Signe Regner, et al.
Publicado: (2018)

A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single Institution
por: Abedi, Armita Armina, et al.
Publicado: (2021)

Implementing targeted therapies in the treatment of glioblastoma: Previous shortcomings, future promises, and a multimodal strategy recommendation
por: Fougner, Vincent, et al.
Publicado: (2022)

The prognostic value of FET PET at radiotherapy planning in newly diagnosed glioblastoma
por: Poulsen, Sidsel Højklint, et al.
Publicado: (2016)

Clinical Characteristics of Gliosarcoma and Outcomes From Standardized Treatment Relative to Conventional Glioblastoma
por: Frandsen, Simone, et al.
Publicado: (2019)

Clinical variables serve as prognostic factors in a model for survival from glioblastoma multiforme: an observational study of a cohort of consecutive non-selected patients from a single institution
por: Michaelsen, Signe Regner, et al.
Publicado: (2013)

Genomic profiling of newly diagnosed glioblastoma patients and its potential for clinical utility – a prospective, translational study
por: Nørøxe, Dorte S., et al.
Publicado: (2020)

Hallmarks of glioblastoma: a systematic review
por: Nørøxe, Dorte Schou, et al.
Publicado: (2017)

The Use of Longitudinal (18)F-FET MicroPET Imaging to Evaluate Response to Irinotecan in Orthotopic Human Glioblastoma Multiforme Xenografts
por: Nedergaard, Mette K., et al.
Publicado: (2014)

Predicting survival of glioblastoma from automatic whole-brain and tumor segmentation of MR images
por: Pálsson, Sveinn, et al.
Publicado: (2022)

Timing of bevacizumab administration after biopsy for unresectable newly diagnosed glioblastoma
por: Matsuda, Masahide, et al.
Publicado: (2022)

The proneural subtype is not associated with survival benefit from bevacizumab in newly diagnosed glioblastoma: a secondary analysis of the GLARIUS trial
por: Weller, Johannes, et al.
Publicado: (2023)

Survival with dacarbazine and fotemustine in newly diagnosed glioblastoma multiforme
por: Fazeny-Dörner, B, et al.
Publicado: (2003)

In silico analysis suggests differential response to bevacizumab and radiation combination therapy in newly diagnosed glioblastoma
por: Hawkins-Daarud, Andrea, et al.
Publicado: (2015)

The prognosis for patients with newly diagnosed glioblastoma receiving bevacizumab combination therapy: a meta-analysis
por: Liao, Ke-Li, et al.
Publicado: (2018)

A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis
por: Chiranth, Shivani, et al.
Publicado: (2023)

Bevacizumab beyond Progression for Newly Diagnosed Glioblastoma (BIOMARK): Phase II Safety, Efficacy and Biomarker Study
por: Nagane, Motoo, et al.
Publicado: (2022)

Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review
por: Henriksson, Roger, et al.
Publicado: (2011)

Progression-Free but No Overall Survival Benefit for Adult Patients with Bevacizumab Therapy for the Treatment of Newly Diagnosed Glioblastoma: A Systematic Review and Meta-Analysis
por: Kaka, Nagham, et al.
Publicado: (2019)

Avelumab in newly diagnosed glioblastoma
por: Jacques, Francois H, et al.
Publicado: (2021)

Differential expression of checkpoint markers in the normoxic and hypoxic microenvironment of glioblastomas
por: Petterson, Stine Asferg, et al.
Publicado: (2022)

Survival impact of delaying postoperative chemoradiotherapy in newly-diagnosed glioblastoma patients
por: Zhang, Maochen, et al.
Publicado: (2020)

Add-on bevacizumab can prevent early clinical deterioration and prolong survival in newly diagnosed partially resected glioblastoma patients with a poor performance status
por: Hata, Nobuhiro, et al.
Publicado: (2017)

Advances in the treatment of newly diagnosed glioblastoma
por: Theeler, Brett J., et al.
Publicado: (2015)

A Review of Newly Diagnosed Glioblastoma
por: Oronsky, Bryan, et al.
Publicado: (2021)

Newly Diagnosed Glioblastoma in Elderly Patients
por: Yuen, Carlen A., et al.
Publicado: (2022)

Impact of time to initiation of radiotherapy on survival after resection of newly diagnosed glioblastoma
por: Katsigiannis, Sotirios, et al.
Publicado: (2019)

A balanced score to predict survival of elderly patients newly diagnosed with glioblastoma
por: Straube, Christoph, et al.
Publicado: (2020)

Comparison of ADC metrics and their association with outcome for patients with newly diagnosed glioblastoma being treated with radiation therapy, temozolomide, erlotinib and bevacizumab
por: Wen, Qiuting, et al.
Publicado: (2014)

Risk of Adverse Vascular Events in Newly Diagnosed Glioblastoma Multiforme Patients Treated with Bevacizumab: a Systematic Review and Meta-Analysis
por: Li, Xiaoqing, et al.
Publicado: (2015)

Plasma YKL-40 as a biomarker for bevacizumab efficacy in patients with newly diagnosed glioblastoma in the phase 3 randomized AVAglio trial
por: Boisen, Mogens K., et al.
Publicado: (2017)

Temozolomide Plus Bevacizumab in Elderly Patients with Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial (ATAG)
por: Reyes‐Botero, Germán, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6eh4m596b6sb6klo9tk44r42db